Vertex Pharmaceuticals Incorporated
Prices may be delayed up to 20 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| VRTX.MX | 068270.KS | 095700.KQ | KRYS | ROIV | 1530.HK | |
|---|---|---|---|---|---|---|
| Market cap | 2.55T | 49.02T | 94.14B | 9.21B | 27.61B | 37.99B |
| P/E (TTM) | 36.7 | — | — | 42.2 | — | 4.1 |
| Forward P/E | — | — | — | 34.0 | -27.5 | 11.2 |
| Price/book | 6.5 | — | — | 6.4 | 6.5 | 1.2 |
| Dividend yield | — | 0.36% | — | — | — | 1.69% |
| 1-year change | +27.27% | +20.07% | −60.56% | +55.44% | +85.85% | −51.32% |
| Today | 0.00% | +7.50% | +0.73% | +1.90% | +6.08% | +4.00% |
The closest companies by business and industry (Biotechnology). Prices may be delayed up to 20 min.
Latest news
All VRTX.MX news ›Vertex: 3 Key Takeaways for Long-Term Investors
Vertex is betting on nephrology and rare endocrinology to build a fifth and fourth commercial pillar beyond cystic fibrosis. Management extended its patient support program (PSP), which provides software and financial assistance for…
Vertex Reports Third Quarter 2026 Financial Results
— Achieved total revenue of $3.44 billion, a 12% increase compared to third quarter 2025 — — Raising full-year revenue guidance to $13.15 billion to $13.25 billion — — Established fourth commercial pillar in rare endocrine diseases with…
More from 1 other outlet
Vertex Pharmaceuticals Q3 Earnings Call Highlights
Posted by Kim Johansen on Nov 3rd, 2026 Vertex Pharmaceuticals (NASDAQ:VRTX) reported third-quarter 2026 revenue growth of 12% year over year, supported by continued cystic fibrosis franchise growth and contributions from newer products…
More from 1 other outlet
Vertex outlines $13.15B-$13.25B 2026 revenue guidance while adding $40M-$50M from Crinetics
Vertex Q3 2026 earnings call: revenue guidance raised, Crinetics boosts growth, and key Pove PDUFA risks loom. Earnings Call Insights: Vertex Pharmaceuticals (VRTX) Q3 2026 “Vertex achieved another quarter of excellent commercial results…
Vertex Pharmaceuticals Non-GAAP EPS of $4.76 misses by $0.02, revenue of $3.44B beats by $10M
Vertex’s financial guidance is summarized below: $13.15 to $13.25 billion vs consensus of $13.28B $13.1 to $13.2 billion $0.5 billion or greater $40 to $50 million $7.15 to $7.2 billion $6.3 to $6.45 billion $5.65 to $5.75 billion
Vertex Pharma's FDA kidney drug ruling: what investors need to know
As seen on the 24/7 Wall St. homepage on November 2, 2026. An FDA decision on povetacicept lands this month, and Kewalramani is already framing kidney disease as Vertex's fifth commercial franchise after cystic fibrosis. The stock has…
Vertex Spends Its CF Growth on New Launches: Rapid Earnings Reaction
Vertex's cystic fibrosis business is still growing, but the company is pouring those gains into new franchises. Here's what the third quarter shows about the cost of building its next act. Vertex Pharmaceuticals (VRTX -1.02%) grew…
Vertex Continues Its Buy-Zone Run After Hiking 2026 Sales Guidance
Allison Gatlin covers biotechnology, pharmaceuticals and medical technology. She also oversees coverage of top-performing companies for Investor's Business Daily's The New America page. Allison has worked for Investor's Business Daily…
Vertex wins MHRA backing for wider Casgevy use
by John Pinching | 3rd Nov 2026 | News Vertex Pharmaceuticals has secured MHRA authorisation and reimbursement for expanded use of Casgevy for eligible children aged 5 to under 12 years with severe sickle cell disease or…
Vertex Pharmaceuticals Incorporated Raises Earnings Guidance for the Full Year 2026
Vertex Pharmaceuticals Incorporated raised earnings guidance for the full year 2026. The company raised its full year 2026 total revenue guidance to $13.15 billion to $13.25 billion from $13.1 billion... Vertex Pharmaceuticals Incorporated…
From the 4Search news index, newest first.
In the news
Mentioned with
People in the coverage
Themes
Most coverage from
- marketscreener.com32
- fool.com11
- seekingalpha.com9
- themarketsdaily.com8
- stocktitan.net6
Finance and business coverage in the 4SEARCH.business news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 120 articles, not a forecast.